{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:36:49Z","timestamp":1778740609380,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recently, the PORT-C and LUNG-ART trials, which evaluated the role of postoperative radiation therapy (PORT), have significantly altered the treatment landscape for NSCLC pN2 patients who previously underwent surgery. In response, the Italian Association of Radiotherapy and Oncology Thoracic Oncology study group has initiated an observational multicenter trial to assess both acute and late toxicities of PORT in pN2 NSCLC patients treated with modern techniques.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data on NSCLC patients submitted to PORT after radical surgery treated between 2015 and 2020 in six Italian Centers were collected. Heart, lung, and esophageal acute and late toxicities have been retrospectively analyzed and related to radiation therapy dosimetric parameters. Furthermore, loco-regional control, distant metastasis and overall survival have been analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 212 patients with a median age of 68\u00a0years from six different centers were included in this analysis (142 males and 70 females). Prior to undergoing PORT, 96 patients (45.8%) had a history of heart disease, 110 patients (51.9%) had hypertension, and 51 patients (24%) had COPD.<\/jats:p>\n                <jats:p>Acute toxicity was observed in 147 patients (69.3%), with lung toxicity occurring in 93 patients (G1 in 70 patients, G2 in 17 patients, and G3 in 4 patients), esophageal toxicity in 114 patients (G1 in 89 patients, G2 in 23 patients, and G3 in 1 patient), and cardiac toxicity in 4 patients (G1 in 2 patients and G3 in 2 patients). Late side effects were found in 60 patients (28.3%), predominantly involving the lungs (51 patients: 32 G1, 11 G2, and 1 G3) and the esophagus (11 patients: 8 G1 and 3 G2), with no reported late cardiac side effects.<\/jats:p>\n                <jats:p>Various clinical and dosimetric parameters were found to correlate with both acute and chronic toxicities. Over a median follow-up period of 54\u00a0months, 48 patients (22.6%) showed locoregional disease relapse, 106 patients (50%) developed distant metastases, and 66 patients (31.1%) died.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RAC-TAC retrospective multicentric study showed the low toxicity of PORT when advanced technology is used. At the same time, it\u2019s noteworthy to underline that 50% of the patients develop distant recurrences in the follow up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11547-024-01885-w","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T14:01:59Z","timestamp":1725112919000},"page":"1700-1709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant modern radiotherapy in resected pN2 NSCLC patients: results from a multicentre retrospective analysis on acute and late toxicity on behalf of AIRO thoracic oncology study group: the RAC-TAC study"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-0965","authenticated-orcid":false,"given":"Valerio","family":"Nardone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Vagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Ciammella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Angrisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Manetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Scricciolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cappabianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"1","key":"1885_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","volume":"23","author":"C Le Pechoux","year":"2022","unstructured":"Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A (2022) Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol 23(1):104\u2013114","journal-title":"Lancet Oncol"},{"issue":"8","key":"1885_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","volume":"7","author":"Z Hui","year":"2021","unstructured":"Hui Z, Men Y, Hu C, Kang J, Sun X, Bi N, Zhou Z, Liang J, Lv J, Feng Q, Xiao Z, Chen D, Wang Y, Li J, Wang J, Gao S, Wang L, He J (2021) Effect of postoperative radiotherapy for patients With pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial. JAMA Oncol 7(8):1178\u20131185","journal-title":"JAMA Oncol"},{"issue":"6","key":"1885_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cllc.2021.08.007","volume":"22","author":"K S\u00fcveg","year":"2021","unstructured":"S\u00fcveg K, Le Pechoux C, Faivre-Finn C, Putora PM, De Ruysscher D, Widder J, Van Houtte P, Troost EGC, Slotman BJ, Ramella S, P\u00f6ttgen C, Peeters STH, Nestle U, McDonald F, Dziadziuszko R, Belderbos J, Ricardi U, Manapov F, Lievens Y, Geets X, Dieckmann K, Guckenberger M, Andratschke N, Glatzer M (2021) Role of postoperative radiotherapy in the management for resected NSCLC\u2014decision criteria in clinical routine pre- and post-lungART. Clin Lung Cancer 22(6):579\u2013586","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1885_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1470-2045(21)00654-9","volume":"23","author":"LEL Hendriks","year":"2022","unstructured":"Hendriks LEL, De Ruysscher DKM (2022) Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART. Lancet Oncol 23(1):8\u20139","journal-title":"Lancet Oncol"},{"issue":"9124","key":"1885_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","volume":"352","author":"PORT Meta-analysis Trialists Group","year":"1998","unstructured":"PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT meta-analysis trialists group. Lancet (Lond, Engl) 352(9124):257\u2013263","journal-title":"Lancet (Lond, Engl)"},{"issue":"4","key":"1885_CR6","first-page":"309","volume":"21","author":"N Ahmad","year":"2009","unstructured":"Ahmad N, Attia G, El-Ghoneimy E, Radwan A, El-Badawy S (2009) Conventional (2D) versus conformal (3D) techniques in radiotherapy for malignant pediatric tumors: dosimetric perspectives. J Egypt Natl Canc Inst 21(4):309\u2013314","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9124","key":"1885_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0140-6736(98)22030-7","volume":"352","author":"AJ Munro","year":"1998","unstructured":"Munro AJ (1998) What now for postoperative radiotherapy for lung cancer? Lancet (Lond, Engl) 352(9124):250\u2013251","journal-title":"Lancet (Lond, Engl)"},{"issue":"19","key":"1885_CR8","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.2005.04.6110","volume":"24","author":"BE Lally","year":"2006","unstructured":"Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clinic Oncol: Offici J Am Soc Clinic Oncol 24(19):2998\u20133006","journal-title":"J Clinic Oncol: Offici J Am Soc Clinic Oncol"},{"issue":"3","key":"1885_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.01.044","volume":"72","author":"JY Douillard","year":"2008","unstructured":"Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA (2008) Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 72(3):695\u2013701","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1885_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.radonc.2010.05.010","volume":"96","author":"V Scotti","year":"2010","unstructured":"Scotti V, Meattini I, Saieva C, Agresti B, de Luca Cardillo C, Bastiani P, Livi L, Mangoni M, Di Cataldo V, Marrazzo L, Rampini A, Cipressi S, Bruni A, Santini P, Biti G (2010) Post-operative radiotherapy in N2 non-small cell lung cancer: a retrospective analysis of 175 patients. Radiother Oncol: J Eur Soc Ther Radiol Oncol 96(1):84\u201388","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"issue":"6","key":"1885_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.21.01774","volume":"40","author":"A Levy","year":"2022","unstructured":"Levy A, Mercier O, Le P\u00e9choux C (2022) Indications and parameters around postoperative radiation therapy for lung cancer. J Clinic Oncol: Off J Am Soc Clinic Oncol 40(6):556\u2013566","journal-title":"J Clinic Oncol: Off J Am Soc Clinic Oncol"},{"key":"1885_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.lungcan.2022.03.009","volume":"166","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Ramella S (2022) Postoperative radiotherapy (PORT) in NSCLC: the end of a love? It is never too good to trust what appears. Lung Cancer (Amst, Nether) 166:250\u2013251","journal-title":"Lung Cancer (Amst, Nether)"},{"issue":"5","key":"1885_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/1759-7714.14335","volume":"13","author":"L Zhu","year":"2022","unstructured":"Zhu L, Xia B, Ma S (2022) Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out. Thorac Cancer 13(5):659\u2013663","journal-title":"Thorac Cancer"},{"issue":"5","key":"1885_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2020.1760094","volume":"20","author":"N Giaj-Levra","year":"2020","unstructured":"Giaj-Levra N, Borghetti P, Bruni A, Ciammella P, Cuccia F, Fozza A, Franceschini D, Scotti V, Vagge S, Alongi F (2020) Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Rev Anticancer Ther 20(5):387\u2013402","journal-title":"Expert Rev Anticancer Ther"},{"key":"1885_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.lungcan.2021.09.010","volume":"161","author":"V Jairam","year":"2021","unstructured":"Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH (2021) Post-operative radiation therapy for non-small cell lung cancer: a comparison of radiation therapy techniques. Lung Cancer (Amst, Neth) 161:171\u2013179","journal-title":"Lung Cancer (Amst, Neth)"},{"issue":"19","key":"1885_CR16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2001.19.19.3912","volume":"19","author":"M Machtay","year":"2001","unstructured":"Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E (2001) Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clinic Oncol: Offici J Am Soc Clinic Oncol 19(19):3912\u20133917","journal-title":"J Clinic Oncol: Offici J Am Soc Clinic Oncol"},{"key":"1885_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2016.10.001","volume":"51","author":"C Billiet","year":"2016","unstructured":"Billiet C, Peeters S, Decaluw\u00e9 H, Vansteenkiste J, Mebis J, Ruysscher D (2016) Postoperative radiotherapy for lung cancer: is it worth the controversy? Cancer Treat Rev 51:10\u201318","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1885_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.lungcan.2004.11.007","volume":"48","author":"HA Wakelee","year":"2005","unstructured":"Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH (2005) Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer (Amst, Nether) 48(3):389\u2013397","journal-title":"Lung Cancer (Amst, Nether)"},{"issue":"4","key":"1885_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/cncr.22845","volume":"110","author":"BE Lally","year":"2007","unstructured":"Lally BE, Detterbeck FC, Geiger AM, Thomas CR, Machtay M, Miller AA, Wilson LD, Oaks TE, Petty WJ, Robbins ME, Blackstock AW (2007) The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 110(4):911\u2013917","journal-title":"Cancer"},{"issue":"1","key":"1885_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2013.08.011","volume":"110","author":"C Billiet","year":"2014","unstructured":"Billiet C, Decaluw\u00e9 H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, De Leyn P, De Ruysscher D (2014) Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiother Oncol: J Eur Soc Ther Radiol Oncol 110(1):3\u20138","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"issue":"4","key":"1885_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.cllc.2016.12.009","volume":"18","author":"JS Remick","year":"2017","unstructured":"Remick JS, Schonewolf C, Gabriel P, Doucette A, Levin WP, Kucharczuk JC, Singhal S, Pechet TTV, Rengan R, SimoneBerman CBAT (2017) First clinical report of proton beam therapy for postoperative radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 18(4):364\u2013371","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1885_CR22","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1016\/j.cllc.2021.02.002","volume":"22","author":"D Boyce-Fappiano","year":"2021","unstructured":"Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ (2021) Single institution experience of proton and photon-based postoperative radiation therapy for non-small-cell lung cancer. Clin Lung Cancer 22(5):e745\u2013e755","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"1885_CR23","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.adro.2023.101213","volume":"8","author":"Z Ma","year":"2023","unstructured":"Ma Z, Liu Y, Bao Y, Yuan M, Yang X, Men Y, Wang J, Deng L, Zhai Y, Bi N, Wang L, Hui Z (2023) Higher lung and heart doses decrease early and long-term survival, respectively, in patients with non-small cell lung cancer undergoing postoperative radiation. Adv Radiat Oncol 8(4):101213","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"1885_CR24","first-page":"100209","volume":"2","author":"AF Shepherd","year":"2021","unstructured":"Shepherd AF, Yu AF, Iocolano M, Leeman JE, Wild AT, Imber BS, Chaft JE, Offin M, Huang J, Isbell JM, Wu AJ, Gelblum DY, Shaverdian N, Simone CB, Gomez D, Yorke E, Jackson A, Rimner A (2021) Increasing heart dose reduces overall survival in patients undergoing postoperative radiation therapy for NSCLC. JTO clinic Res Rep 2(8):100209","journal-title":"JTO clinic Res Rep"},{"issue":"10308","key":"1885_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet (Lond, Engl) 398(10308):1344\u20131357","journal-title":"Lancet (Lond, Engl)"},{"issue":"10","key":"1885_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, Valli\u00e8res E, Mart\u00ednez-Mart\u00ed A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA (2023) Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol: Offici J Eur Soc Med Oncol 34(10):907\u2013919","journal-title":"Ann Oncol: Offici J Eur Soc Med Oncol"},{"issue":"10","key":"1885_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O'Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23(10):1274\u20131286","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"1885_CR28","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8581","volume":"36","author":"JE Chaft","year":"2018","unstructured":"Chaft JE, Dahlberg SE, Khullar OV, Edelman MJ, Simone CB, Heymach J, Rudin CM, Ramalingam SS (2018) EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). J Clinic Oncol 36(15_suppl):8581\u20138581","journal-title":"J Clinic Oncol"},{"issue":"9","key":"1885_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/imt-2021-0019","volume":"13","author":"JM Sands","year":"2021","unstructured":"Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE (2021) Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy 13(9):727\u2013734","journal-title":"Immunotherapy"},{"issue":"21","key":"1885_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386(21):1973\u20131985","journal-title":"N Engl J Med"},{"issue":"6","key":"1885_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodr\u00edguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD (2023) Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 389(6):491\u2013503","journal-title":"N Engl J Med"},{"key":"1885_CR32","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.050","volume":"34","author":"T Cascone","year":"2023","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Provencio Pulla M (2023) LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC. Ann Oncol 34:S1295","journal-title":"Ann Oncol"},{"issue":"3","key":"1885_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S (2024) Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA 331(3):201\u2013211","journal-title":"JAMA"},{"issue":"3","key":"1885_CR34","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","volume":"23","author":"JV Heymach","year":"2022","unstructured":"Heymach JV, Mitsudomi T, Harpole D, Aperghis M, Jones S, Mann H, Fouad TM, Reck M (2022) Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN trial. Clin Lung Cancer 23(3):e247\u2013e251","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"1885_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","volume":"16","author":"K Banfill","year":"2021","unstructured":"Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, Sun F, Vozenin MC, Faivre Finn C (2021) Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol: Offici Public Int Assoc Study Lung Cancer 16(2):216\u2013227","journal-title":"J Thorac Oncol: Offici Public Int Assoc Study Lung Cancer"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01885-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T18:07:25Z","timestamp":1731348445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01885-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01885-w","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have no other relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Hospital Vanvitelli, Naples, under Protocol Number 0026796\/I dated September 21, 2021 and then from all the other participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}